Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
182 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06216301 | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC(LUNAR-2) | recruiting | Phase 3 | 734 | NovoCure GmbHINDUSTRY | 16 | Jun 25, 2026 | clinicaltrials |
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | recruiting | — | 9,000 | Genzyme, a Sanofi CompanyINDUSTRY | 44 | Jun 23, 2026 | clinicaltrials |
| NCT05929885 | Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients | recruiting | Phase 2 | 50 | National Cancer Centre, SingaporeOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05696626 | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation(ELAINEIII) | recruiting | Phase 3 | 600 | LeonaBioINDUSTRY | 17 | Jun 22, 2026 | clinicaltrials |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | recruiting | Phase 1 | 180 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 17, 2026 | clinicaltrials |
| NCT07116161 | Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore | recruiting | N/A | 100 | National Cancer Centre, SingaporeOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07615036 | AP-NOSES: A Prospective Multicentre Registry of Natural Orifice Specimen Extraction in Minimally Invasive Colorectal Surgery(AP-NOSES) | recruiting | — | 800 | Singapore General HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT03093116 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements(TRIDENT-1) | recruiting | Phase 1 / Phase 2 | 500 | Turning Point Therapeutics, Inc.INDUSTRY | 19 | May 27, 2026 | clinicaltrials |
| NCT05384626 | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | recruiting | Phase 1 / Phase 2 | 840 | Nuvalent Inc.INDUSTRY | 15 | May 27, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma(JADE) | recruiting | Phase 3 | 864 | GlaxoSmithKlineINDUSTRY | 31 | May 26, 2026 | clinicaltrials |
| NCT05724264 | SingapOre Lung Cancer Screening Through Integrating CT With Other biomarkErs (SOLSTICE) | recruiting | N/A | 1,000 | National Cancer Centre, SingaporeOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06766058 | Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy. | recruiting | N/A | 300 | National Cancer Centre, SingaporeOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(TROPION-Lung15) | recruiting | Phase 3 | 744 | AstraZenecaINDUSTRY | 27 | May 14, 2026 | clinicaltrials |
| NCT02806388 | Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project(IMPACT) | recruiting | — | 5,500 | National Cancer Centre, SingaporeOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06956248 | Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)(IMPACT-INSPIRE) | recruiting | — | 50 | National Cancer Centre, SingaporeOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06023862 | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)(DOVE) | recruiting | Phase 2 | 198 | Yonsei UniversityOTHER | 7 | May 6, 2026 | clinicaltrials |
| NCT06044441 | Evaluation and Implementation Preparation of a Proactive Palliative Care Model (ENABLE-SG)(ENABLE-SG) | recruiting | N/A | 715 | National Cancer Centre, SingaporeOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06051409 | A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) | recruiting | Phase 3 | 350 | Ascentage Pharma Group Inc.INDUSTRY | 12 | Apr 30, 2026 | clinicaltrials |
| NCT05580562 | ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)(ACTION) | recruiting | Phase 3 | 510 | Jazz PharmaceuticalsINDUSTRY | 18 | Apr 16, 2026 | clinicaltrials |
| NCT06093061 | Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | recruiting | Phase 2 | 53 | National Cancer Centre, SingaporeOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04686305 | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC(DL03) | recruiting | Phase 1 | 304 | AstraZenecaINDUSTRY | 19 | Apr 13, 2026 | clinicaltrials |
| NCT05183984 | Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer(NIRVANA-1) | recruiting | Phase 2 | 390 | ARCAGY/ GINECO GROUPOTHER | 6 | Apr 13, 2026 | clinicaltrials |
| NCT07319676 | Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas | recruiting | Phase 1 / Phase 2 | 30 | National University Hospital, SingaporeOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04988555 | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | recruiting | Phase 1 / Phase 2 | 606 | Sumitomo Pharma America, Inc.INDUSTRY | 12 | Mar 24, 2026 | clinicaltrials |
| NCT05730036 | A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma(LINKER-MM3) | recruiting | Phase 3 | 410 | Regeneron PharmaceuticalsINDUSTRY | 18 | Mar 6, 2026 | clinicaltrials |
| NCT07428356 | Histotripsy for Ablation of Liver Tumours in Asia(HALT) | recruiting | N/A | 40 | National Cancer Centre, SingaporeOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07133269 | Care Coach-led Integrated Palliative Surgical Oncology and Rehabilitation Care Model for Advanced Cancer Patients | recruiting | N/A | 770 | Singapore General HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05701527 | A Study of EBC-129 in Advanced Solid Tumours | recruiting | Phase 1 | 98 | EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesOTHER_GOV | 3 | Feb 5, 2026 | clinicaltrials |
| NCT07358715 | Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals | recruiting | N/A | 140 | National University Hospital, SingaporeOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07162415 | Ganglion Resection Effectiveness Trial(GangLion) | recruiting | N/A | 220 | Tampere University HospitalOTHER | 2 | Jan 21, 2026 | clinicaltrials |
| NCT07282808 | Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer(FLAME-PC) | recruiting | N/A | 130 | Singapore General HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06392477 | A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 96 | SanofiINDUSTRY | 5 | Dec 23, 2025 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT06645678 | Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma(MELT-MM) | recruiting | Phase 1 / Phase 2 | 75 | YOUNGIL KOHOTHER | 2 | Dec 3, 2025 | clinicaltrials |
| NCT05377034 | Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients(STRATUM) | recruiting | Phase 2 | 100 | National Cancer Centre, SingaporeOTHER | 4 | Oct 6, 2025 | clinicaltrials |
| NCT05037331 | Osimertinib for Advanced EGFR-positive NSCLC Patients | recruiting | — | 58 | National University Hospital, SingaporeOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05305131 | Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer | recruiting | Phase 2 | 50 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05381038 | Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | recruiting | Phase 1 / Phase 2 | 10 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05532397 | Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma | recruiting | N/A | 10 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06977360 | Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solution for Women With Breast Cancer Undergoing Chemotherapy (iCareBreast+): A Pilot Study Research Proposal | recruiting | N/A | 40 | National Cancer Centre, SingaporeOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05957068 | Breast Cancer Exercise Intervention Study(BREXINT) | recruiting | N/A | 2,156 | National Cancer Centre, SingaporeOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06160843 | Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma(POLAR) | recruiting | Phase 2 | 24 | National Cancer Centre, SingaporeOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05181033 | Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor | recruiting | Phase 2 | 120 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05719428 | Neural Network-based Treatment Decision Support Tool in Patients With Refractory Solid Organ Malignancies(DRUID) | recruiting | Phase 2 | 37 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06513624 | ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers(ETC-159-02) | recruiting | Phase 1 | 16 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06846268 | Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer | recruiting | Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials